welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study
study id #: NCT01712152
condition: Carrier of Duchenne Muscular Dystrophy
Carriers of Duchenne muscular dystrophy (DMD) often have no severe symptoms of the scelet muscles, but they may develop a poor heart function due to the involvement of the heart muscle. Ultrasound of the heart is recommended, but it can detect a cardiac affection only after the heart has already become weaker. Cardiac magnetic resonance tomography can detect myocardial fibrosis already at preserved heart function and may facilitate early therapy. In our study, diagnosed carriers of DMD will undergo examinations of the heart by blood tests, EKG, heart ultrasound and magnetic resonance at enrollment and after one year in order to assess the extent of cardiac affection and its association with the clinical development.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: October 2012
estimated completion: April 2014
size / enrollment: 20
- T1 mapping [ Time Frame: 1 year ]
T1 mapping by MOLLI sequences will be performed and compared between study entry and one year follow-up
- left ventricular function [ Time Frame: 1 year ]
left ventricular function on MRI will be compared between study entry and one year follow-up
genetic and/or histological identification as a carrier of DMD age above 18 years able and willing to conform to the requirements of the study provided written informed consent exclusion of pregnancy in women of childbearing potential
Claustrophobia Excessive obesity to an extent where CMR cannot be performed Chronic renal failure with a GFR <30 ml/min/1,73m² Implanted pacemakers/defibrillators Severe arrhythmia Inability to cooperate during the CMR Known intolerance to gadolinium Positive pregnancy test Unable or unwilling to conform to the study protocol
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in D...Santhera Pharmaceuticals announces that ...
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
“Watching time tick by…”: Decision making for Duchenne muscular dystrophy trialsObjective:This interview study explored ...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dyst...Duchenne Muscular Dystrophy (DMD) is inh...
Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With ...Background: - Children with Duchenne/Bec...